Published in Lab Business Week, May 13th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Genmab.
Report 1: Genmab A/S announced new insights into the novel mechanisms of action of its antibody HuMax-EGFr(TM) (zalutumumab). By using Protein Tomography(TM), a relatively new technology which uses an electron microscope to view the three dimensional structure of proteins on the surface of cells, HuMax-EGFr was shown to lock the EGF receptor in an inactive conformation which prevents receptor activation and the binding of growth factors. Furthermore, HuMax- EGFr was shown to inhibit EGF receptor...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.